US regulators order a vision-loss warning onto GLP-1 labels
The FDA wants a rare eye condition named on the labels of Ozempic, Wegovy and the rest of the class. Here is what the alert says — and what it can't.
The US Food and Drug Administration has told the makers of GLP-1 medicines to add a warning about a rare eye condition to their labels, the BBC reported this week. The condition is non-arteritic anterior ischaemic optic neuropathy — NAION, in practice — where the blood supply to the optic nerve drops and sight in one eye can go, usually without any pain.
Putting it in the warnings and precautions section of the label is the FDA's way of saying: this is rare, we can't rule it out, and the people prescribing and taking these drugs should know the word.
The agency's review drew on trial data, animal work and reports from people taking the drugs after they reached the market. It also leant on a pooled look at 126 trials covering more than 134,000 patients, in which the eye problem turned up more often in people on these medicines than in those who weren't.
That is a signal, not a mechanism. Pooled trial data can show a pattern without explaining why it happens, and NAION has other well-documented causes — high blood pressure, diabetes, sleep apnoea, an unusually crowded optic disc — several of which are common in the very people who get prescribed weight-loss drugs.
What a label warning does is put the possibility in front of a prescriber at the moment they hand over the box, which is more than most of us get from a headline.
The practical bit is unglamorous. Sudden painless loss of sight in one eye, or a shadow creeping across it, is not something to sleep on — that is an eye casualty conversation today, whether or not you are on a GLP-1.
What it found
- The US Food and Drug Administration identified 15 probable cases of non-arteritic anterior ischemic optic neuropathy across 288,879 person-years of clinical trial data.
- The estimated incidence rate was 6.4 cases per 100,000 person-years for GLP-1 users versus 3.8 cases for comparators.
- Retrospective analysis showed a higher risk for GLP-1 users compared to those taking DPP-4 inhibitors, though the risk was not statistically significant when compared to SGLT-2 inhibitors.
What it can't tell us
The total number of identified cases is small, and the agency describes the risk as potential rather than definitively proven. The findings are based on observational data and meta-analyses, which cannot establish a direct causal mechanism.
If you're on it
If you notice any sudden, painless changes in your vision, you should contact your healthcare provider immediately for an urgent evaluation.
Sources
Every brief is written from scratch. We summarise and link rather than reproducing anyone's article, abstract, table or image, and any direct quote is short and attributed. Read the original before you draw conclusions from a summary — including ours. Not medical advice. If something feels wrong, speak to a clinician or call 111.